# A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

> **NCT00190931** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 400 (—)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Atomoxetine Hydrochloride
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00190931
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 400 (—)
- **Last updated:** 2006-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190931, "A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00190931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*